T-cell receptor (TCR) engineering is an advanced technique in vaccinology that focuses on modifying T cells to enhance the immune response against specific pathogens or tumors. T cells play a crucial role in identifying and killing infected or cancerous cells. By engineering the TCRs on these cells, scientists can improve their ability to recognize and target pathogens more effectively. This technique is particularly important in the development of vaccines for diseases like cancer and chronic infections, where the immune system may not respond efficiently to the pathogen. By enhancing TCR specificity and affinity, researchers can create vaccines that stimulate a stronger, more targeted immune response. This method is being explored in several cancer immunotherapies and infectious disease vaccines, offering the potential for personalized medicine and more effective treatments for diseases that have traditionally been difficult to target.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States